Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a debilitating rare disease affecting children and young adults. Dynacure’s development program is using an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals. The company was founded in 2016 as a spin-off from the IGBMC (Institute of Genetic and Molecular and Cellular Biology – Unistra/INSERM/CNRS) of Strasbourg. Dynacure today announcesthe appointment of its new Management Team and members of the Board of Directors.
Dynacure’s leadership team includes Stephane van Rooijen (CEO), Frédéric Legros (COO) and Leen Thielemans (Head of Development). The team will focus on the company’s preclinical and clinical development programs in CNM and the expansion of its pipeline in rare disease treatments.
Stephane has an extensive experience in the life sciences orphan biotech industry, previously working at Genzyme, Viropharma-Shire and Confo Therapeutics. He has a medical degree from the University of Leuven in Belgium and obtained an MBA at the Erasmus University Rotterdam and Georgetown University of Washington DC.
Frédéric has over a decade of experience in business development and strategic management. Before joining Dynacure, Frédéric was Vice President and Corporate Head of Business Development at Valneva SE. Frédéric obtained his PhD in molecular biology in 2002 at the Institute of Myology in Paris. He also holds a business degree from NEOMA business school, France.
Leen brings with her over fifteen years of experience in pharmaceutical R&D, from drug discovery to early clinical development. Leen previously worked at Johnson & Johnson, 4AZAElbion, Movetis, and Shire. Leen Thielemans is a bio-engineer from the University of Leuven and an epidemiologist with a PhD in medical sciences.
Dynacure’s Board of Directors has six members: Frederic Chereau, Chris Mirabelli and Brett Monia, who have been appointed as independent directors, Rémi Droller and Vanessa Malier, who represent Kurma Partners, and Stephane van Rooijen (CEO).
Frederic has over 25 years of experience and acknowledged leadership in the orphan life sciences industry and previously worked at aTyr, Shire, Pervasis and Genzyme. He holds a B.S. in Physics from Paris University and obtained a Master’s degree in Management from La Rochelle Business School in France and an M.B.A. from INSEAD, Fontainebleau, France.
Chris is an internationally-recognized biotech entrepreneur, was a co-founder of Ionis Pharmaceuticals and currently holds board positions in a number of US biotechnology companies. He received his PhD in Molecular Pharmacology from the Baylor College of Medicine and obtained a B.S. degree in Biology from the State University of New York at Fredonia.
Brett is a founding member of Ionis, he is the Franchise Leader for programs in Oncology and Rare Genetic Diseases, and head of Drug Discovery at Ionis Pharmaceuticals. Dr. Monia received his PhD in Pharmacology at the University of Pennsylvania and holds B.S. degrees in Molecular Biology and Analytical Chemistry
Remi Droller, Chairman of Dynacure’s Board of Directors said: “We are very proud of the creation of this new rare disease biotech company, which is the result of cooperation between several major players in the life sciences field. With the expertise of its management, board of directors and Ionis Pharmaceuticals antisense platform, Dynacure is ready to deliver its development targets.”
Stephane van Rooijen, CEO of Dynacure added: “Dynacure is well positioned to drive forward its lead program in Centronuclear Myopathies. We now plan to focus on the expansion of our portfolio in order to develop new therapeutic approaches and help patients who suffer from rare debilitating diseases.”
Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a rare, debilitating disease affecting children and young adults. Dynacure’s Dyn101 development program is based on the modulation of the expression of the Dynamin 2 protein through the use of an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals, the leading biopharmaceutical company in RNA-targeted drug discovery.
Dynacure was founded in 2016 as a spin-off from the IGBMC (Institute of Genetic and Molecular and Cellular Biology – Unistra/INSERM/CNRS) of Strasbourg.
NewCap – Media Relations
+33(0)1 44 71 94 98
Stephane van Rooijen, CEO